Last Updated : May 15, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Vimizim | Elosulfase alfa | Mucopolysaccharidosis IVA (Morquio A syndrome) | Do not list | Complete | ||
| Triumeq | Dolutegravir / abacavir / lamivudine | HIV Infection | List with criteria/condition | Complete | ||
| Juxtapid | Lomitapide | Hypercholesterolemia, homozygous familial | Do not list | Complete | ||
| Treanda (in combination with rituximab) | Bendamustine hydrochloride | Chronic Lymphocytic Leukemia | Withdrawn | |||
| Cimzia | Certolizumab pegol | Ankylosing spondylitis | List with criteria/condition | Complete | ||
| Inflectra | Infliximab | Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis | List with criteria/condition | Complete | ||
| Bosulif | Bosutinib | Chronic Myeloid Leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Remsima | Infliximab | Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis | Withdrawn | |||
| Picato | Ingenol mebutate | Actinic keratosis | N/A | Complete | ||
| Prezcobix | Darunavir/cobicistat | HIV Infection | List with criteria/condition | Complete |
Last Updated : May 15, 2024